Comprehensive database of marijuana prices across legal U.S. states, including both recreational and medical cannabis markets.

Health Canada collects data on cannabis under the Cannabis Tracking System Ministerial Order. Data collected is for these types of cannabis in the legal industry: dried cannabis, edible cannabis, cannabis extracts, cannabis topicals, cannabis plants and cannabis seeds. Data categories includes: medical sales, non-medical sales, packaged inventory, unpackaged inventory and licensed area.

Key investor reporting supports Health Canada's ability to protect the integrity of the strict legal framework for the cannabis industry, and helps to minimize the risk of cannabis being diverted to an illicit market. It also helps reduce opportunities for organized crime to infiltrate the legal industry through financial investments.

Canadian cannabis market data for all legal cannabis sales as well as for medical, non-medical sales, inventory and cultivation area data.

Canadian cannabis market data for all legal cannabis sales as well as for medical, non-medical sales, inventory and cultivation area data.

Introduction: The unmet need for highly effective, naturally derived products with minimal side effects results in the over-popularity of ever-newer medicinal plants. In the middle of 2010, products containing cannabidiol (CBD), one of the special metabolites of Cannabis sativa, started to gain popularity. For consumers and healthcare providers alike, the legal context surrounding the marketing of CBD products is not entirely clear, and the safety of using some products is in doubt. Companies in the online medicinal product market profit from the confusion around CBD oils.Methods: In our study, we employed a complex method known as risk-based safety mapping of the online pharmaceutical market, which included health claim content analysis of online stores, test purchases, and labeling and quantitative analysis of the CBD content.Results: There were discovered 16 online retailers selling an average of 2–7 goods and CBD oils with a concentration of 3%–5% (30–50 mg/mL) CBD. The majority (n/N = 10/16, 62.5%) displayed potential health-related benefits indirectly on their website, and in the case of one web shop (n/N = 1/16, 6.3%), we detected COVID-19-related use. Altogether, 30 types of purported “indications” were collected. A total of 12 CBD oil products were test-purchased from online retailers in December 2020. Upon evaluating the packaging and product information, we noticed that three products (n/N = 3/12, 25%) lacked instructions on use, hence increasing the risk of inappropriate application and dosing. The cannabidiol content was quantified using UHPLC. The measured CBD concentrations of the products ranged from 19.58 mg/mL to 54.09 mg/mL (mean 35.51 mg/mL, median 30.63 mg/mL, and SD ± 12.57 mg/mL). One (8.33%) product was underlabeled, five (41.67%) were over-labeled, and only every second product (50%) was appropriately labeled based on the quantitative assessment of CBD concentration.Discussion: Further research and quality control are necessary to establish the regulatory context of the usage and classification of CBD and other cannabinoids in nonmedicinal products (e.g., food supplements), as authorities and policymakers worldwide struggle with the uncertainties surrounding CBD products.